TheraRadar
Data updated: Mar 29, 2026

BEVYXXA

BETRIXABAN
Approved 2017-06-23
1
Indication
--
Phase 3 Trials
1
Priority Reviews
8
Years on Market

Details

Status
Discontinued
First Approved
2017-06-23
Routes
ORAL
Dosage Forms
CAPSULE

Companies

Active Ingredient: BETRIXABAN

BEVYXXA Approval History

Loading approval history...

What BEVYXXA Treats

1 FDA approvals

Originally approved for its first indication in 2017 .

  • Other (1)
๐Ÿ”ฌ

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...
โญ

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
๐Ÿ“Š

Trial Timeline

Full development history with FDA approval milestones

|
Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

BEVYXXA FDA Label Details

Pro

BEVYXXA Patents & Exclusivity

Latest Patent: Mar 2031

Patents (24 active)

US8404724 Expires Mar 29, 2031
US8987463 Expires Dec 28, 2030
US8557852 Expires Sep 8, 2028
US7598276 Expires Nov 8, 2026
US9555023 Expires Nov 7, 2026
+ 14 more patents
Source: FDA Orange Book

Want competitive intelligence?

See who's developing similar drugs and track their progress

View Pipeline Dashboard

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.